News Releases

IBBR Receives $1.2M NIH Award to Develop 3D Modeling Tool That Could Lead to New Immunotherapies

DMF5 TCR, shown in complex with  its target, has been in clinical trials for melanoma immunotherapy.  Pierce and collaborators redesigned this TCR  to improve its tumor targeting.

New computational tool supports the engineering and development of cancer immunotherapies

IBBR Researcher, Dr. Alexander Andrianov, Receives Funding for Two Collaborations

Collaborations will explore using two novel types of biofunctional synthetic macromolecules of the polyphosphazene (PPZ) family for exciting and very different applications. In the first, PPZs will be developed for use as biocompatible and drug-releasing hydrophobic coatings for indwelling medical devices.

Targeting HIV: Moving closer to a potential cure

Tri-specific antibody targets and neutralizes 99.5% of HIV-1 virus strains

A team of researchers at IBBR, led by Dr. Yuxing Li, Associate Professor at the University of Maryland School of Medicine, Baltimore, and Principal Investigator at the Institute for Bioscience and Biotechnology Research (IBBR), Rockville, is showing how engineered multi-specific antibodies appear to be highly effective at preventing infection across a broad range of HIV-1 virus strains.

IBBR Receives Grant to Explore Next Generation Multi-Specific Antibody Therapeutic: Next Step towards a Cure for HIV?

The goal is to develop and test a “first-in-class multi-specific antibody“, which could offer dramatic advantages over current treatments for AIDS patients, help eliminate hidden reservoirs of HIV, and potentially deliver on the promise of a long-awaited HIV cure.

IBBR Awarded $6 Million NIH Grant for Structure-Based Design of a Hepatitis C Vaccine

(Rockville, MD, June 12, 2017) University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $6.0 million grant entitled, “Structure-Based Vaccine Design for Hepatitis C Virus”, to develop a novel prophylactic vaccine to prevent hepatitis C virus (HCV) infection. The grant is funded by the National Institutes of Health (NIH) and the research will take place over a five-year period.